Episode Details

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s recent up to $400 million private placement financing and the next major milestones for vidofludimus calcium in multiple sclerosis. Vitt described the transaction as “a great transaction and a transformative transaction for the company,” explaining that the $200 million upfront tranche strengthens Immunic’s position ahead of its pivotal phase 3 ENSURE readouts and supports preparations for potential commercialization. The financing is designed to fund completion of the phase 3 ENSURE trials in relapsing MS, support a planned NDA submission to the FDA in mid-next year, and enable the initiation of a new phase 3 study in primary progressive MS. Immunic expects topline data from its twin phase 3 ENSURE studies at the end of this year. Vitt noted that an interim analysis conducted in 2024 resulted in the IDMC giving the studies the green light to continue as planned. For more interviews and insights from the biotech sector, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content. #ImmunicInc #DanielVitt #MultipleSclerosis #RelapsingMS #PrimaryProgressiveMS #VidofludimusCalcium #Phase3Trials #BiotechNews #NDA #ClinicalTrials #HealthcareInvesting